Long-term safety of adalimumab in clinical trials in adult patients with Crohn’s disease or ulcerative colitis.

Long-term safety of adalimumab in clinical trials in adult patients with Crohn’s disease or ulcerative colitis. Aliment Pharmacol Ther. 2017 Nov 21;: Authors: Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H Abstract BACKGROUND: Adalimumab is used to treat moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC) when conventional therapies fail. AIM: To update long-term adalimumab safety from CD and UC trials; the previous report was…

Read More

Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn’s disease.

Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017 Nov 21;: Authors: Vande Casteele N, Feagan BG, Vermeire S, Yassine M, Coarse J, Kosutic G, Sandborn WJ Abstract BACKGROUND: Therapeutic drug monitoring may optimize therapy for Crohn’s disease (CD). AIM: To use a population pharmacokinetic model that accounts for the time-varying nature of covariates to simulate certolizumab pegol (CZP) concentrations to evaluate the exposure-response relationship for CZP in Crohn’s disease. METHODS: Adults (N = 2157) with Crohn’s disease were treated with CZP in…

Read More

Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.

Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Aliment Pharmacol Ther. 2017 Nov 09;: Authors: Bar-Yoseph H, Levhar N, Selinger L, Manor U, Yavzori M, Picard O, Fudim E, Kopylov U, Eliakim R, Ben-Horin S, Chowers Y, Ungar B Abstract BACKGROUND: Primary nonresponse, defined as lack of clinical benefit during the induction phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms underlying primary nonresponse have not yet been clearly defined. AIM: To evaluate the association of early (week 2…

Read More

Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn’s disease-Authors’ reply.

Related Articles Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn’s disease-Authors’ reply. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1121 Authors: Feathers A, Swaminath A, Ananthakrishnan AN, Falzon L, Li Ferry S PMID: 29105134 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29105134?dopt=Abstract

Read More

Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn’s disease.

Related Articles Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn’s disease. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1119-1120 Authors: Logan M, Ijaz UZ, Hansen R, Gerasimidis K, Russell RK PMID: 29105140 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29105140?dopt=Abstract

Read More

Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients.

Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients. Aliment Pharmacol Ther. 2017 Oct 24;: Authors: Nordenvall C, Olén O, Nilsson PJ, von Seth E, Ekbom A, Bottai M, Myrelid P, Bergquist A Abstract BACKGROUND: Despite the close relationship between primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD), the association between colectomy and the prognosis of PSC remains controversial. AIM: To explore whether colectomy prior to PSC-diagnosis is associated with transplant-free survival. METHODS: A nationwide cohort…

Read More

Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn’s disease-Authors’ reply.

Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn’s disease-Authors’ reply. Aliment Pharmacol Ther. 2017 Nov;46(10):1026-1027 Authors: Feathers A, Swaminath A, Ananthakrishnan AN, Falzon L, Li Ferry S PMID: 29052855 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29052855?dopt=Abstract

Read More

Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn’s disease.

Related Articles Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017 Oct 20;: Authors: Lang BM, Biedermann L, van Haaften WT, de Vallière C, Schuurmans M, Begré S, Zeitz J, Scharl M, Turina M, Greuter T, Schreiner P, Heinrich H, Kuntzen T, Vavricka SR, Rogler G, Beerenwinkel N, Misselwitz B, Swiss IBD Cohort Study Group Abstract BACKGROUND: Smoking is a strong environmental factor leading to adverse outcomes in Crohn’s disease, but a more benign course in ulcerative colitis. Several…

Read More

The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis.

Related Articles The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther. 2017 Oct 20;: Authors: Kump P, Wurm P, Gröchenig HP, Wenzl H, Petritsch W, Halwachs B, Wagner M, Stadlbauer V, Eherer A, Hoffmann KM, Deutschmann A, Reicht G, Reiter L, Slawitsch P, Gorkiewicz G, Högenauer C Abstract BACKGROUND: Faecal microbiota transplantation is an experimental approach for the treatment of patients with ulcerative colitis. Although there is growing evidence that faecal microbiota…

Read More
<< Go Back